Skip to main content

Table 1 Variations in glycans determined through lectin microarray analysis of the A2780 cells and A2780-cp cells

From: Lectin array and glycogene expression analyses of ovarian cancer cell line A2780 and its cisplatin-resistant derivate cell line A2780-cp

No.

Lectin

Preferred glycan structure (terminal epitope)

A2780-1 ± SD

CP-1 ± SD

C1/A1

A2780-2 ± SD

CP-2 ± SD

C2/A2

1

LTL

Fuc α1-3(Gal β1-4)GlcNAc (Lex), Fuc α1-2(Gal β1-4)GlcNAc

0.58 ± 0.02

0.62 ± 0.01

1.07**

0.47 ± 0.02

0.41 ± 0.02

0.86*

2

PSA

Fuc α1-6GlcNAc, α-D-Glc, α-D-Man

0.90 ± 0.03

1.06 ± 0.02

1.17***

0.94 ± 0.04

1.05 ± 0.07

1.11

3

LCAa

Fuc α1-6GlcNAc, α-D-Glc, α-D-Man

0.86 ± 0.04

0.99 ± 0.03

1.15***

1.02 ± 0.02

1.21 ± 0.08

1.19**

4

UEA-I

Fuc α1-2(Gal β1-4)GlcNAc

0.43 ± 0.02

0.52 ± 0.02

1.20***

0.48 ± 0.01

0.34 ± 0.00

0.71***

5

AOLa

Fuc α1-6GlcNAc (core Fuc), Fuc α1-2(Gal β1-4)GlcNAc

0.49 ± 0.02

0.47 ± 0.01

0.96***

0.52 ± 0.03

0.46 ± 0.02

0.87*

6

AAL

Fuc α1-6GlcNAc (core Fuc), Fuc α1-3(Gal β1-4)GlcNAc (Lex)

0.80 ± 0.03

0.86 ± 0.04

1.07***

1.04 ± 0.09

0.78 ± 0.02

0.76*

7

MAL

Sia α2-3Gal β1-4GlcNAc

0.69 ± 0.01

0.75 ± 0.01

1.10***

0.61 ± 0.01

0.56 ± 0.01

0.91**

8

SNAa

Sia α2-6Gal/GalNAc

1.01 ± 0.07

0.83 ± 0.03

0.82**

0.94 ± 0.02

0.72 ± 0.04

0.77***

9

SSAa

Sia α2-6Gal/GalNAc

0.95 ± 0.02

0.77 ± 0.02

0.81***

0.94 ± 0.01

0.67 ± 0.01

0.71***

10

TJA-I

Sia α2-6Gal/GalNAc

1.98 ± 0.10

1.44 ± 0.10

0.73***

1.16 ± 0.04

1.38 ± 0.06

1.19***

11

PHA-L

Tri/Tetra-antennary complex-type N-glycan

0.62 ± 0.02

0.69 ± 0.01

1.12**

0.58 ± 0.02

0.49 ± 0.01

0.85***

12

ECA

Gal β1-4GlcNAc

1.26 ± 0.04

1.22 ± 0.05

0.97*

0.98 ± 0.03

0.99 ± 0.05

1.01

13

RCA120

Gal β1-4GlcNAc

2.36 ± 0.09

1.65 ± 0.12

0.70***

1.97 ± 0.11

2.47 ± 0.23

1.25***

14

PHA-E

Complex-type N-glycans with outer Gal and bisecting GlcNAc

1.11 ± 0.02

1.15 ± 0.03

1.03

1.04 ± 0.05

1.55 ± 0.05

1.50***

15

DSA

(GlcNAc β1-4)n, Gal β1-4GlcNAc, Tri/Tetra-antennary N-glycans

2.57 ± 0.03

2.65 ± 0.09

1.03

1.58 ± 0.06

2.29 ± 0.14

1.45***

16

GSL-II

Agalactosylated tri/tetra antennary glycans, GlcNAc

0.43 ± 0.02

0.52 ± 0.02

1.20***

0.48 ± 0.02

0.31 ± 0.01

0.66***

17

NPAa

High Man, Man α1-6Man

1.30 ± 0.02

1.47 ± 0.05

1.13***

1.29 ± 0.08

1.85 ± 0.14

1.43***

18

ConAa

High Man, Man α1-6(Man α1-3)Man (inhibited by presence of bisecting GlcNAc)

1.46 ± 0.08

2.05 ± 0.03

1.40***

1.93 ± 0.16

2.19 ± 0.15

1.13**

19

GNAa

High Man, Man α1-3Man

1.05 ± 0.04

1.12 ± 0.05

1.07***

0.97 ± 0.04

1.27 ± 0.11

1.30***

20

HHL

High Man, Man α1-3Man, Man α1-6Man

0.75 ± 0.02

0.75 ± 0.02

0.99

0.82 ± 0.02

0.76 ± 0.04

0.92*

21

ACG

Sia α2-3Gal β1-4GlcNAc

1.45 ± 0.04

1.37 ± 0.07

0.94

1.55 ± 0.06

1.74 ± 0.13

1.12**

22

TxLC-I

Man3 core, bi- and tri-antennary complex-type N-glycan, GalNAc

0.64 ± 0.02

0.72 ± 0.02

1.13**

0.75 ± 0.02

0.68 ± 0.04

0.90

23

BPLa

Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc

0.82 ± 0.02

0.60 ± 0.01

0.73***

0.58 ± 0.01

0.52 ± 0.03

0.89*

24

TJA-IIa

Fuc α1-2Gal β1-4, GalNAcβ1-4 groups at their nonreducing terminals

1.24 ± 0.03

0.89 ± 0.01

0.72***

1.19 ± 0.06

0.78 ± 0.09

0.65**

25

EEL

Gal α1-3Gal β1-4GlcNAc, Fuc α1-2(Gal α1-3)Galβ1-4GlcNAc

0.44 ± 0.02

0.52 ± 0.02

1.17***

0.41 ± 0.02

0.30 ± 0.02

0.72**

26

ABA

Gal β1-3GalNAc (α-Thr/Ser (T)), GlcNAc, sialyl-T

0.86 ± 0.01

0.94 ± 0.01

1.09***

1.01 ± 0.04

0.94 ± 0.05

0.93*

27

LELa

(GlcNAc β1-4)n, (Gal β1-4GlcNAc)n (polyLacNAc)

3.22 ± 0.28

3.65 ± 0.14

1.13*

2.37 ± 0.08

3.26 ± 0.18

1.37**

28

STLa

(GlcNAc)n, (GlcNAc β1-4MurNAc)n (peptidoglycan backbone)

2.72 ± 0.21

2.95 ± 0.22

1.09***

1.48 ± 0.06

2.00 ± 0.13

1.35***

29

UDA

GlcNAc β1-4GlcNAc, Mixture of Man5 to Man9

1.97 ± 0.22

1.65 ± 0.13

0.84**

1.72 ± 0.06

1.97 ± 0.18

1.14*

30

PWMa

(GlcNAc α1-4)n

0.78 ± 0.08

0.52 ± 0.03

0.67***

0.71 ± 0.03

0.39 ± 0.04

0.54***

31

Jacalin

Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn))

1.02 ± 0.07

1.13 ± 0.08

1.11

1.50 ± 0.05

1.89 ± 0.18

1.25**

32

PNA

Gal β1-3GalNAc (α-Thr/Ser (T))

0.40 ± 0.02

0.41 ± 0.03

1.02

0.62 ± 0.02

0.40 ± 0.02

0.64***

33

WFAa

Terminal GalNAc (e.g. GalNAcβ1-4GlcNAc), Galβ1-3(-6)GalNAc

0.94 ± 0.08

0.59 ± 0.02

0.62***

0.79 ± 0.03

0.44 ± 0.02

0.55***

34

ACA

Gal β1-3GalNAc (α-Thr/Ser (T))

0.87 ± 0.06

1.21 ± 0.07

1.39***

1.26 ± 0.05

1.25 ± 0.04

0.99

35

MPA

Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn))

0.61 ± 0.06

0.70 ± 0.06

1.15***

1.12 ± 0.04

0.58 ± 0.03

0.52***

36

HPA

α-Linked terminal GalNAc

0.42 ± 0.04

0.56 ± 0.04

1.33***

0.74 ± 0.02

0.51 ± 0.05

0.69**

37

VVA

α-Linked terminal GalNAc (α-Thr/Ser (Tn), GalNAc α1-3Gal

0.46 ± 0.01

0.45 ± 0.02

0.99

0.87 ± 0.05

0.51 ± 0.02

0.58***

38

DBA

GalNAc α1-3GalNAc (Blood group A), GalNAc α1-3GalNAc

0.40 ± 0.01

0.44 ± 0.01

1.11***

0.61 ± 0.05

0.37 ± 0.02

0.61***

39

SBAa

α or β-linked terminal GalNAc, GalNAc α1-3Gal

0.49 ± 0.00

0.42 ± 0.02

0.85**

0.80 ± 0.09

0.53 ± 0.05

0.66***

40

Calsepa

High Man (Man2-6), N-glycans including bisecting GlcNAc

0.59 ± 0.01

0.59 ± 0.00

1.01

1.15 ± 0.11

0.90 ± 0.07

0.79**

41

PTL-I

α-Linked terminal GalNAc

0.52 ± 0.01

0.51 ± 0.01

0.99

0.75 ± 0.05

0.52 ± 0.04

0.70***

42

MAH

Sia α2-3Gal β1-3(Sia α2-6) GalNAc

0.48 ± 0.01

0.52 ± 0.02

1.10*

0.45 ± 0.00

0.37 ± 0.02

0.83**

43

WGA

(GlcNAcβ1-4)n, NeuAc, multivalent Sia

1.26 ± 0.01

1.12 ± 0.04

0.89**

1.26 ± 0.03

1.39 ± 0.07

1.11*

44

GSL-IA4

α-GalNAc (α-Thr/Ser (Tn))

0.39 ± 0.01

0.49 ± 0.01

1.26***

0.69 ± 0.07

0.37 ± 0.02

0.54**

45

GSL-IB4

α-Gal

0.39 ± 0.01

0.49 ± 0.00

1.25***

0.87 ± 0.05

0.65 ± 0.03

0.74***

  1. aSignificant changes in the two experiments. * p < 0.05; ** p < 0.01; *** p < 0.001